Our partner is focused on developing therapies for rare and autoimmune diseases. Their approach targets key drivers of inflammation to address unmet medical needs, with the goal of improving patient outcomes and quality of life through innovative treatments.

This critical hire led the research in barrier biology and innate immunity, providing scientific leadership to support clinical-stage programs focused on innate immunity modulation. They identified and validated new targets in disease-relevant pathways, driving discovery efforts and preclinical portfolio development. With over 10 years of experience in cell biology or immunology, they contributed to transitioning discovery research into clinical development, ensuring alignment with unmet medical needs.